Recombinant ITGA5 (Volociximab Biosimilar) anticorps

N° du produit ABIN5668271

Cet anticorps Lapin Chimeric détecte spécifiquement ITGA5 (Volociximab Biosimilar) dans FACS, BR, ELISA, IF, IHC (p) et IHC (fro). Il présente une réactivité avec des échantillons de Humain.

Aperçu rapide pour Recombinant ITGA5 (Volociximab Biosimilar) anticorps (ABIN5668271)

Antigène: ITGA5 (Volociximab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Lapin

Clonalité: Chimeric

Conjugué: Inconjugué

Application: Flow Cytometry (FACS), Blocking Reagent (BR), ELISA, Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Clone: M200

Détail du produit

Fonction: Anti-alpha 5 beta 1 Integrin [M200 (Volociximab)], Rabbit IgG, kappa

Specificité:

This antibody is specific for human α5β1 integrin. Cross-reactivity studies revealed no binding to other human integrins such as α3β1, αvβ3, or αvβ5. It does, however, bind to α5β1 in the vasculature of cynomolgus monkeys, but not in mice. α5β1 is part of the integrin superfamily-glycoprotein transmembrane receptors that interact with ligands such as fibronectin, vitronectin, laminins, and collagens. This receptor plays a key role in processes including inflammation, cell proliferation, angiogenesis, and tumor metastasis.

Application Notes original Clone: This antibody binds human α5β1 integrin with high affinity (Kd = 0.367 nM, EC₅₀ = 0.2 nM, IC₅₀ = 2.3 nM) and, in chimeric mouse-human IgG4 form, demonstrated potent anti angiogenic and anti tumor effects in preclinical models (laser induced CNV in cynomolgus monkeys, VX2 carcinoma in rabbits) before progressing into Phase II trials in platinum resistant ovarian cancer (Ramakrishnan et al., 2006, PMID: 17024968, Bhaskar et al., 2007, PMID: 17786386). Exclusive binding to α5β1 (no cross reactivity with α3β1, αvβ3, αvβ5) was confirmed by ELISA. Immunohistochemistry (IHC-F) demonstrated binding to cynomolgus vasculature but not to mouse tissue. Studies with recombinant integrin subunits revealed that binding depends specifically on the human α5 chain, while the β1 chain can be of either human or mouse origin, indicating strict specificity for the α5β1 heterodimer (Bukowski et al., 2009, DOI: 10.1007/978-1-59745-332-5). In clinical testing, weekly 15 mg/kg IV dosing achieved trough serum levels >150 μg/mL, with 2-3x accumulation by Day 50, detectable antibody in ascites, reduction in circulating endothelial progenitor cells, and a favorable safety profile. The use of this antibody in IHC-P was demostrated (Bell McGuinn et al., 2011, PMID: 21276608). Clone F200, a Fab derivative of M200, is available upon request.

Attributs du produit: NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques.

Purification: Protein A affinity purified

Pureté: > 98 % as determined by SDS-PAGE

niveau d'endotoxine: Endotoxin is < 1.0 EU/mg as determined by the LAL method

Immunogène: Heterodimeric alpha5beta1Fc fusion protein

Isotype: IgG, kappa

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Commentaires:

OriginalSpeciesName: Human

OriginalFormat: IgG4

Restrictions: For Research Use only

Stockage

Concentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Détail du antigène

Antigène: ITGA5 (Volociximab Biosimilar)

Classe de substances: Biosimilar

Sujet: Fibronectin receptor, CD49 antigen-like family member E, Integrin alpha-F, VLA-5, CD49e.

UniProt: P08648